The European Commission is market testing Thomson Reuters’ commitments regarding its Reuters Instrument Codes (RICs). The commitments are to resolve the Commission’s concerns that Thomson Reuters is abusing its dominant position in the market for consolidated real-time datafeeds. RICs are used by financial institutions to identify securities and their trading locations. Among other uses, RICs are used to retrieve data from Thomson Reuters’ real-time datafeeds.
The Commission is of the view that Thomson Reuters may be prohibiting its customers from using the RICs to get data from alternative providers and cross-referencing the RICs to alternative codes by other suppliers. Such practices create and substantially heighten switching barriers for customers.
Thomson Reuters offers to allow customers to license additional RIC usage rights for switching purposes. In addition, customers may use RICs to retrieve data from alternative providers and Thomson Reuters will provide the necessary information to cross-reference RICs to alternative codes. The commitments improve upon an earlier proposal, which was found to be flawed in a first market test, by extending the scope of the license to cover all RICs and reducing the license fee.
Full content: EC Press Release
Related content: Coordination and Lock-In: Competition with Switching Costs and Network Effects
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas